# Oropharynx (OPX) Biomarker Trial

> **NCT06356272** · — · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 560 (estimated)

## Conditions studied

- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Metastatic Oropharyngeal Squamous Cell Carcinoma
- Oropharyngeal Squamous Cell Carcinoma
- Recurrent Oropharyngeal Squamous Cell Carcinoma
- Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Head and Neck Carcinoma
- Head and Neck Neoplasm
- Salivary Gland Neoplasms
- Thyroid Gland Neoplasm

## Interventions

- **OTHER:** Non-Interventional Study

## Key facts

- **NCT ID:** NCT06356272
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2019-11-15
- **Primary completion:** 2029-11-30
- **Final completion:** 2029-11-30
- **Target enrollment:** 560 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06356272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06356272, "Oropharynx (OPX) Biomarker Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06356272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*